ImmunityBio stock price: IBRX ticks up in premarket after ANKTIVA sales surge and new approvals
ImmunityBio shares rose about 1% premarket Tuesday after reporting 2025 ANKTIVA net product revenue of $113 million, up 700% year over year. The stock surged 13% Monday on heavy volume. ANKTIVA is now authorized for bladder cancer in 33 countries and recently received conditional approval for lung cancer in Saudi Arabia. The company ended 2025 with a net loss of $351.4 million and $242.8 million in cash.